The webinar oversimplified. Individual US-citizen ownership is one path — it isn't the only one. Being VC-majority doesn't automatically disqualify you.

The "US citizens only" framing is the exact wording that makes eligible firms self-disqualify. 13 C.F.R. 121.702 allows four ownership branches: (1) >50% by individuals who are citizens/permanent residents; (2) >50% by other qualifying small businesses; (3) — at agencies that elected the authority — >50% by multiple VCOCs / hedge funds / PE firms; and (4) ANCs, NHOs, or Indian Tribes. VC-backed and tribally owned firms can absolutely qualify.

Two conditions on the VC path: no single VC/hedge/PE firm may own >50% (unless it is itself a qualifying small business), and the firm must register with SBA before its Phase I/II proposal. It's also agency-scoped — only at agencies that elected 15 U.S.C. 638(dd); the participating list is authoritative, not the blog consensus.

500 is the cap for SBIR, so at 480 you'd be under it — just count your employees.

Not quite — and this is where firms get surprised. The size standard is 500 employees together with all affiliates, not your headcount alone (13 C.F.R. 121.103). The real test is control: a controlling investor (a PE firm, or a common owner across companies) can cause SBA to aggregate an entire portfolio's employees into your count. Affiliation — not raw headcount — is what busts the cap.

One SBIR-specific relief: a firm is not affiliated with a VC/hedge/PE firm's other portfolio companies solely because they share an investor (13 C.F.R. 121.702) — but affiliation can still arise for other reasons (common control, board seats, identity of interest). Family-owned entities that do business together are presumed affiliated too (121.103(f)).

A sole proprietorship is eligible — but form a real entity anyway (LLC at minimum, C-corp if you'll raise): it separates liability, it's what reviewers and investors expect, and it cleans up who owns the IP. Get IP counsel before you spend on the prototype.

The thread's confident "you must assign the patent / 51% US manufacturing" is wrong, and it scares people off. Under Bayh-Dole, the small business elects to retain title — you are not forced to assign your invention. The "manufactured substantially in the US" rule (35 U.S.C. 204 / 37 CFR 401.14(i)) attaches only to an exclusive license to use or sell in the US, and it's waivable. Not a blanket 51% mandate.

The right people forget: SBIR gives you a 20-year data-rights protection period from date of award (uniform, non-extendable; DoD codified it in DFARS effective Jan 2025). After it, the government holds Government Purpose Rights — not unlimited.

First pass: it's not about being foreign-born. It's undisclosed ties to a country of concern — surfaced by the agency's screening. Owners, key personnel, investors, subcontractors, even old co-authorships. Fix it with a mitigation plan and resubmit.

Partially wrong, and in the dangerous direction. At HHS/NIH there is no pre-award cure. seed.nih.gov states the agency will not give you a chance to address a security risk before the award decision. A mitigation plan is pre-submission defense — not a rescue for a flagged proposal. If flagged, you reapply next cycle.

Countries of concern = exactly four. Anything else is speculation until State designates it.

TABA = Technical and Business Assistance. It's money for commercialization help your R&D dollars can't cover — up to $6,500 on Phase I and up to $50,000 on Phase II (per project). You request it in the proposal.

Right on the caps — but the April 2026 reauthorization changed the game, and old guides miss it: TABA is now mandated across all 11 agencies, you pick your own vendor (no more agency funnel), and there is no approved-vendor list. New allowed uses include cybersecurity and foreign-risk screening. And "$5k on top vs taken out" is agency-specific — Phase I is often additive, Phase II is often deducted. Read your solicitation.

Two constraints people miss: TABA can carry no profit/fee for the small business and can't go in G&A; and you must already be an awardee — TABA is post-award, tied to your project. Before spending it, the SBA says check what the free innovation network (FAST, SBDC, APEX) covers.

Real reasons exist: opportunity cost (a 6–10 month cycle at low odds), fit (SBIR funds innovation the agency needs, not a product tweak), and compliance capacity (grant accounting; FAR/DCAA for contracts).

1. "SBIR is one thing." It isn't. A DoD/DoW SBIR is a production-style contract for a capability they already want; an NSF/NIH SBIR is an open call to fund a good idea. Wrong door + wrong mindset is why most people bounce off.

2. "The program is dead." Stale — the thread predates the reauthorization. SBIR is authorized through 2031, with anti-"mill" proposal caps from FY2027.

3. "It won't scale me, so it's worthless." Half right. It won't scale you — but every non-dilutive dollar taken before selling equity is raised at zero dilution and de-risks the round that does.

Grounding the odds: Phase I success runs ~15–25% by agency, ~17% overall. NIH is the most competitive (15–18%, and the most applications — 3,500+/yr); NSF and DoD land in the same band. Real, but not a lottery.